Tasly Pharmaceutical Group Co (SHSE:600535) LT-Debt-to-Total-Asset : 0.02 (As of Sep. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tasly Pharmaceutical Group Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.02.

Tasly Pharmaceutical Group Co's long-term debt to total assets ratio declined from Sep. 2023 (0.10) to Sep. 2024 (0.02). It may suggest that Tasly Pharmaceutical Group Co is progressively becoming less dependent on debt to grow their business.

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Chart

Tasly Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.14

0.07

0.09

Tasly Pharmaceutical Group Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.09	0.09	0.07	0.02

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Calculation

Tasly Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1495.585	/	16714.285
	=	0.09

Tasly Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	301.478	/	16834.745
	=	0.02

Tasly Pharmaceutical Group Co (SHSE:600535) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tasly Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410

Website

http://www.tasly.com

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Executives

Wu Nai Feng

Director

Tasly Pharmaceutical Group Co Headlines

No Headlines